JP2002501072A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002501072A5 JP2002501072A5 JP2000528572A JP2000528572A JP2002501072A5 JP 2002501072 A5 JP2002501072 A5 JP 2002501072A5 JP 2000528572 A JP2000528572 A JP 2000528572A JP 2000528572 A JP2000528572 A JP 2000528572A JP 2002501072 A5 JP2002501072 A5 JP 2002501072A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- dihydro
- chlorophenyl
- brs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 263
- 125000001931 aliphatic group Chemical group 0.000 description 218
- 238000000034 method Methods 0.000 description 204
- 125000003118 aryl group Chemical group 0.000 description 179
- 238000005160 1H NMR spectroscopy Methods 0.000 description 168
- -1 small molecule compounds Chemical class 0.000 description 118
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 89
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 84
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 74
- 239000000047 product Substances 0.000 description 62
- LZAYOZUFUAMFLD-UHFFFAOYSA-N 4-(4-chlorophenyl)-4-hydroxypiperidine Chemical compound C=1C=C(Cl)C=CC=1C1(O)CCNCC1 LZAYOZUFUAMFLD-UHFFFAOYSA-N 0.000 description 57
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 57
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 55
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 54
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 53
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 48
- 239000002904 solvent Substances 0.000 description 48
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 47
- 239000000243 solution Substances 0.000 description 45
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 43
- 239000000203 mixture Substances 0.000 description 42
- 230000002829 reductive effect Effects 0.000 description 34
- 239000011541 reaction mixture Substances 0.000 description 31
- 239000011780 sodium chloride Substances 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 125000002252 acyl group Chemical group 0.000 description 27
- 229910052757 nitrogen Inorganic materials 0.000 description 27
- 239000007864 aqueous solution Substances 0.000 description 26
- 229920006395 saturated elastomer Polymers 0.000 description 26
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 24
- 235000019341 magnesium sulphate Nutrition 0.000 description 24
- 125000004433 nitrogen atom Chemical group N* 0.000 description 24
- 239000012044 organic layer Substances 0.000 description 24
- 125000001072 heteroaryl group Chemical group 0.000 description 23
- 238000010898 silica gel chromatography Methods 0.000 description 23
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 102000019034 Chemokines Human genes 0.000 description 22
- 108010012236 Chemokines Proteins 0.000 description 22
- 238000001994 activation Methods 0.000 description 21
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 20
- 108010055166 Chemokine CCL5 Proteins 0.000 description 20
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 201000010099 disease Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 230000004913 activation Effects 0.000 description 19
- 210000000265 leukocyte Anatomy 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000005557 antagonist Substances 0.000 description 18
- 102000009410 Chemokine receptor Human genes 0.000 description 17
- 108050000299 Chemokine receptor Proteins 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 229910052736 halogen Inorganic materials 0.000 description 17
- 150000002367 halogens Chemical class 0.000 description 17
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 17
- DXNYSMPOOHDCMD-UHFFFAOYSA-N 11-(3-bromopropylidene)-5,6-dihydrodibenzo[2,1-b:2',1'-f][7]annulene Chemical compound C1CC2=CC=CC=C2C(=CCCBr)C2=CC=CC=C21 DXNYSMPOOHDCMD-UHFFFAOYSA-N 0.000 description 16
- 102000000013 Chemokine CCL3 Human genes 0.000 description 16
- 230000006870 function Effects 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 108700012434 CCL3 Proteins 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 238000010992 reflux Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 125000006575 electron-withdrawing group Chemical group 0.000 description 13
- WAQHMFBPFLNJNQ-UHFFFAOYSA-N 7-methoxy-6h-[1]benzoxepino[2,3-b]pyridin-5-one Chemical compound O1C2=NC=CC=C2C(=O)CC2=C1C=CC=C2OC WAQHMFBPFLNJNQ-UHFFFAOYSA-N 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- 230000007115 recruitment Effects 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 11
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- 230000002159 abnormal effect Effects 0.000 description 10
- 238000009739 binding Methods 0.000 description 10
- ADEKJVNFIQUGRR-UHFFFAOYSA-N 4h-pyridin-3-one Chemical compound O=C1CC=CN=C1 ADEKJVNFIQUGRR-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000004093 cyano group Chemical group *C#N 0.000 description 9
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 9
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 9
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 7
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 125000004076 pyridyl group Chemical group 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 210000001616 monocyte Anatomy 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 5
- 102000001902 CC Chemokines Human genes 0.000 description 5
- 108010040471 CC Chemokines Proteins 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000035605 chemotaxis Effects 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- BYOIMOJOKVUNTP-UHFFFAOYSA-N spiro[1h-2-benzofuran-3,4'-piperidine] Chemical compound C12=CC=CC=C2COC21CCNCC2 BYOIMOJOKVUNTP-UHFFFAOYSA-N 0.000 description 5
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Substances C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- KSZKJGKTCSHPOS-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-[3-(2-methoxy-6h-benzo[c][1]benzoxepin-11-ylidene)propyl]piperidin-4-ol Chemical compound C12=CC(OC)=CC=C2OCC2=CC=CC=C2C1=CCCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 KSZKJGKTCSHPOS-UHFFFAOYSA-N 0.000 description 4
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 4
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
- 125000002837 carbocyclic group Chemical group 0.000 description 4
- 239000002975 chemoattractant Substances 0.000 description 4
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- DMEGYFMYUHOHGS-UHFFFAOYSA-N cycloheptane Chemical group C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 4
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 4
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- MLCZLOSZWUXPEM-UHFFFAOYSA-N 5-(3-bromopropylidene)-7-methoxy-6h-[1]benzoxepino[2,3-b]pyridine Chemical group O1C2=NC=CC=C2C(=CCCBr)CC2=C1C=CC=C2OC MLCZLOSZWUXPEM-UHFFFAOYSA-N 0.000 description 3
- BWBQQIJIIIGGAN-UHFFFAOYSA-N 5-[3-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]propylidene]-6h-[1]benzoxepino[2,3-b]pyridin-7-ol Chemical compound C1C=2C(O)=CC=CC=2OC2=NC=CC=C2C1=CCCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 BWBQQIJIIIGGAN-UHFFFAOYSA-N 0.000 description 3
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 3
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 3
- 108050006947 CXC Chemokine Proteins 0.000 description 3
- 102000019388 CXC chemokine Human genes 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 238000001525 receptor binding assay Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 2
- 0 *C1CCNCC1 Chemical compound *C1CCNCC1 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- RTJFIGSGLFRXIX-UHFFFAOYSA-N 2h-1-benzoxepin-5-one Chemical compound O=C1C=CCOC2=CC=CC=C12 RTJFIGSGLFRXIX-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- SXOMHACGFSJBIO-UHFFFAOYSA-N 4-(4-chlorophenyl)-1,2,3,6-tetrahydropyridine Chemical compound C1=CC(Cl)=CC=C1C1=CCNCC1 SXOMHACGFSJBIO-UHFFFAOYSA-N 0.000 description 2
- VPONIANJHJUUKE-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-[3-(2-hydroxy-6h-benzo[c][1]benzoxepin-11-ylidene)propyl]piperidin-4-ol Chemical compound C12=CC(O)=CC=C2OCC2=CC=CC=C2C1=CCCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 VPONIANJHJUUKE-UHFFFAOYSA-N 0.000 description 2
- VKQHTSSNSJIMAL-UHFFFAOYSA-N 4-(4-chlorophenyl)piperidine Chemical compound C1=CC(Cl)=CC=C1C1CCNCC1 VKQHTSSNSJIMAL-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- FAJGWBHDKADUHW-UHFFFAOYSA-N 5h-benzo[c][1]benzazepine Chemical compound N1C=C2C=CC=CC2=CC2=CC=CC=C12 FAJGWBHDKADUHW-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 2
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 description 2
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 description 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 2
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 2
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000001326 Chemokine CCL4 Human genes 0.000 description 2
- 108010055165 Chemokine CCL4 Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- 101710139422 Eotaxin Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 102100036154 Platelet basic protein Human genes 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 229910001516 alkali metal iodide Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 229960004405 aprotinin Drugs 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 108010086192 chymostatin Proteins 0.000 description 2
- 108010035886 connective tissue-activating peptide Proteins 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
- 108010052968 leupeptin Proteins 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- YNLFEVAOQLXINF-UHFFFAOYSA-N methylsulfanylmethane;tribromoborane Chemical compound CSC.BrB(Br)Br YNLFEVAOQLXINF-UHFFFAOYSA-N 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229910052760 oxygen Chemical group 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 1
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical class O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- QDVBKXJMLILLLB-UHFFFAOYSA-N 1,4'-bipiperidine Chemical compound C1CCCCN1C1CCNCC1 QDVBKXJMLILLLB-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- MRBFGEHILMYPTF-UHFFFAOYSA-N 1-(2-Pyrimidyl)piperazine Chemical compound C1CNCCN1C1=NC=CC=N1 MRBFGEHILMYPTF-UHFFFAOYSA-N 0.000 description 1
- BVKKRWPRNWNKTH-UHFFFAOYSA-N 1-(2-chlorophenyl)sulfonylpiperazine Chemical compound ClC1=CC=CC=C1S(=O)(=O)N1CCNCC1 BVKKRWPRNWNKTH-UHFFFAOYSA-N 0.000 description 1
- BLZOIBGTCWDWIL-UHFFFAOYSA-N 1-(3-chlorophenyl)sulfonylpiperazine Chemical compound ClC1=CC=CC(S(=O)(=O)N2CCNCC2)=C1 BLZOIBGTCWDWIL-UHFFFAOYSA-N 0.000 description 1
- CKVKEBVACPUEIB-UHFFFAOYSA-N 1-(4-chlorophenyl)sulfonylpiperazine Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)N1CCNCC1 CKVKEBVACPUEIB-UHFFFAOYSA-N 0.000 description 1
- WKRVLDRFLKDBFU-UHFFFAOYSA-N 1-[3-(6h-[1]benzothiepino[2,3-b]pyridin-5-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol Chemical compound C1CN(CCC=C2C3=CC=CN=C3SC3=CC=CC=C3C2)CCC1(O)C1=CC=C(Cl)C=C1 WKRVLDRFLKDBFU-UHFFFAOYSA-N 0.000 description 1
- DAVYUIGPWXYQCR-UHFFFAOYSA-N 1-[3-(6h-benzo[c][1]benzoxepin-11-ylidene)propyl]-4-(4-chlorophenyl)piperidin-4-ol Chemical compound C1CN(CCC=C2C3=CC=CC=C3OCC3=CC=CC=C32)CCC1(O)C1=CC=C(Cl)C=C1 DAVYUIGPWXYQCR-UHFFFAOYSA-N 0.000 description 1
- XTIGGAHUZJWQMD-UHFFFAOYSA-N 1-chloro-2-methoxyethane Chemical compound COCCCl XTIGGAHUZJWQMD-UHFFFAOYSA-N 0.000 description 1
- XPDSXKIDJNKIQY-UHFFFAOYSA-N 1-cyclohexylpiperazine Chemical compound C1CCCCC1N1CCNCC1 XPDSXKIDJNKIQY-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- HTQWGIHCFPWKAS-UHFFFAOYSA-N 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical group C1CNCCC11C(=O)NCN1C1=CC=CC=C1 HTQWGIHCFPWKAS-UHFFFAOYSA-N 0.000 description 1
- ZGZYDGWWZPMTPN-UHFFFAOYSA-N 11-(3-bromopropylidene)-2-methoxy-6h-benzo[c][1]benzoxepine Chemical compound O1CC2=CC=CC=C2C(=CCCBr)C2=CC(OC)=CC=C21 ZGZYDGWWZPMTPN-UHFFFAOYSA-N 0.000 description 1
- QTANJTBTGWWAJP-UHFFFAOYSA-N 11-(3-bromopropylidene)-5h-benzo[c][1]benzazepin-6-one Chemical compound N1C(=O)C2=CC=CC=C2C(=CCCBr)C2=CC=CC=C21 QTANJTBTGWWAJP-UHFFFAOYSA-N 0.000 description 1
- JSAFBLUKXUHDKN-UHFFFAOYSA-N 11-(3-bromopropylidene)-5h-pyrido[2,3-c][2]benzazepin-6-one Chemical compound N1C(=O)C2=CC=CC=C2C(=CCCBr)C2=CC=CN=C21 JSAFBLUKXUHDKN-UHFFFAOYSA-N 0.000 description 1
- LXWDIXXWJPGCOI-UHFFFAOYSA-N 11-(3-bromopropylidene)-6h-benzo[c][1]benzoxepin-2-ol Chemical compound O1CC2=CC=CC=C2C(=CCCBr)C2=CC(O)=CC=C21 LXWDIXXWJPGCOI-UHFFFAOYSA-N 0.000 description 1
- GNKCQOOXORIZGS-UHFFFAOYSA-N 11-(3-bromopropylidene)dibenzo[1,2-a:1',2'-e][7]annulene Chemical compound C1=CC2=CC=CC=C2C(=CCCBr)C2=CC=CC=C21 GNKCQOOXORIZGS-UHFFFAOYSA-N 0.000 description 1
- ADBBRBSGMJNNQH-UHFFFAOYSA-N 11-[3-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]propylidene]-6h-benzo[c][1]benzoxepine-2-carbonitrile Chemical compound C1CN(CCC=C2C3=CC(=CC=C3OCC3=CC=CC=C32)C#N)CCC1(O)C1=CC=C(Cl)C=C1 ADBBRBSGMJNNQH-UHFFFAOYSA-N 0.000 description 1
- MFRULYMPACSJAB-UHFFFAOYSA-N 11h-[1]benzoxepino[4,3-c]pyridin-5-one Chemical compound O=C1OC2=CC=CC=C2CC2=CN=CC=C12 MFRULYMPACSJAB-UHFFFAOYSA-N 0.000 description 1
- VPUSSTHXXTXSIM-UHFFFAOYSA-N 11h-[1]benzoxepino[4,3-d]pyrimidin-5-one Chemical compound O=C1OC2=CC=CC=C2CC2=NC=NC=C12 VPUSSTHXXTXSIM-UHFFFAOYSA-N 0.000 description 1
- HJNHUFQGDJLQRS-UHFFFAOYSA-N 2-(3-bromopropoxy)oxane Chemical compound BrCCCOC1CCCCO1 HJNHUFQGDJLQRS-UHFFFAOYSA-N 0.000 description 1
- VQMGNNHZJHNZSH-UHFFFAOYSA-N 2-[[5-(3-piperidin-1-ylpropylidene)-6h-[1]benzoxepino[2,3-b]pyridin-7-yl]oxy]ethyl acetate Chemical compound C1C=2C(OCCOC(=O)C)=CC=CC=2OC2=NC=CC=C2C1=CCCN1CCCCC1 VQMGNNHZJHNZSH-UHFFFAOYSA-N 0.000 description 1
- DNDFNIYCQIQAIO-UHFFFAOYSA-N 2-[[5-[3-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]propylidene]-6h-[1]benzoxepino[2,3-b]pyridin-7-yl]oxy]-1-morpholin-4-ylethanone Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCC=C(C1=CC=CN=C1OC1=CC=C2)CC1=C2OCC(=O)N1CCOCC1 DNDFNIYCQIQAIO-UHFFFAOYSA-N 0.000 description 1
- NKSJOIMYFBPCOX-UHFFFAOYSA-N 2-[[5-[3-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]propylidene]-6h-[1]benzoxepino[2,3-b]pyridin-7-yl]oxy]acetonitrile Chemical compound C1CN(CCC=C2C3=CC=CN=C3OC3=CC=CC(OCC#N)=C3C2)CCC1(O)C1=CC=C(Cl)C=C1 NKSJOIMYFBPCOX-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
- RGHQKFQZGLKBCF-UHFFFAOYSA-N 2-bromoethyl acetate Chemical compound CC(=O)OCCBr RGHQKFQZGLKBCF-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylamino-1-chloro-ethane hydrochloride Natural products CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 1
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- SAQGGUMGWGCEHW-UHFFFAOYSA-N 2-hydroxy-6h-benzo[c][1]benzoxepin-11-one Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(O)=CC=C21 SAQGGUMGWGCEHW-UHFFFAOYSA-N 0.000 description 1
- GTFOTXQFXHOBJY-UHFFFAOYSA-N 2-methoxy-6h-benzo[c][1]benzoxepin-11-one Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC(OC)=CC=C21 GTFOTXQFXHOBJY-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical class C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- FEKPQWCDELSHHJ-UHFFFAOYSA-N 2-piperidin-4-ylphenol Chemical compound OC1=CC=CC=C1C1CCNCC1 FEKPQWCDELSHHJ-UHFFFAOYSA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- XUUSYXJGMRQBKQ-UHFFFAOYSA-N 2h-2-benzazepine Chemical compound N1C=CC=C2C=CC=CC2=C1 XUUSYXJGMRQBKQ-UHFFFAOYSA-N 0.000 description 1
- CIRSPTXGPFAXRE-UHFFFAOYSA-N 3-(1,2,3,6-tetrahydropyridin-4-yl)-1h-indole Chemical compound C1NCCC(C=2C3=CC=CC=C3NC=2)=C1 CIRSPTXGPFAXRE-UHFFFAOYSA-N 0.000 description 1
- RCAHJTSKECMBPQ-UHFFFAOYSA-N 3-(7-methoxy-6h-[1]benzoxepino[2,3-b]pyridin-5-ylidene)prop-2-enal Chemical compound O1C2=NC=CC=C2C(=C=CC=O)CC2=C1C=CC=C2OC RCAHJTSKECMBPQ-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- DZTFRKRYNMTWBQ-UHFFFAOYSA-N 3-bromo-11-(3-bromopropylidene)-6h-benzo[c][1]benzoxepine Chemical compound C1OC2=CC(Br)=CC=C2C(=CCCBr)C2=CC=CC=C21 DZTFRKRYNMTWBQ-UHFFFAOYSA-N 0.000 description 1
- HMCFOZAMMWTLJU-UHFFFAOYSA-N 3-bromo-6h-benzo[c][1]benzoxepin-11-one Chemical compound O1CC2=CC=CC=C2C(=O)C2=CC=C(Br)C=C12 HMCFOZAMMWTLJU-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- BYNBAMHAURJNTR-UHFFFAOYSA-N 3-piperidin-4-yl-1h-benzimidazol-2-one Chemical compound O=C1NC2=CC=CC=C2N1C1CCNCC1 BYNBAMHAURJNTR-UHFFFAOYSA-N 0.000 description 1
- KAIRZPVWWIMPFT-UHFFFAOYSA-N 3-piperidin-4-yl-1h-indole Chemical compound C1CNCCC1C1=CNC2=CC=CC=C12 KAIRZPVWWIMPFT-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- NBJHDLKSWUDGJG-UHFFFAOYSA-N 4-(2-chloroethyl)morpholin-4-ium;chloride Chemical compound Cl.ClCCN1CCOCC1 NBJHDLKSWUDGJG-UHFFFAOYSA-N 0.000 description 1
- AYSRDSVZHJXCLD-UHFFFAOYSA-N 4-(2-chlorophenyl)piperidin-4-ol Chemical compound C=1C=CC=C(Cl)C=1C1(O)CCNCC1 AYSRDSVZHJXCLD-UHFFFAOYSA-N 0.000 description 1
- CHFUSNXDQCWMGF-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)piperidin-4-ol Chemical compound C=1C=C(Cl)C(Cl)=CC=1C1(O)CCNCC1 CHFUSNXDQCWMGF-UHFFFAOYSA-N 0.000 description 1
- HFYYZUZJEADDED-UHFFFAOYSA-N 4-(3,4-difluorophenyl)-1-[3-(7-methoxy-6h-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol Chemical compound C1C=2C(OC)=CC=CC=2OC2=NC=CC=C2C1=CCCN(CC1)CCC1(O)C1=CC=C(F)C(F)=C1 HFYYZUZJEADDED-UHFFFAOYSA-N 0.000 description 1
- PRUOWMZBJQVWEG-UHFFFAOYSA-N 4-(3,4-difluorophenyl)piperidin-4-ol Chemical compound C=1C=C(F)C(F)=CC=1C1(O)CCNCC1 PRUOWMZBJQVWEG-UHFFFAOYSA-N 0.000 description 1
- OQGVHCXIDRSNHF-UHFFFAOYSA-N 4-(3,5-dichlorophenyl)piperidin-4-ol Chemical compound C=1C(Cl)=CC(Cl)=CC=1C1(O)CCNCC1 OQGVHCXIDRSNHF-UHFFFAOYSA-N 0.000 description 1
- PDJGUVHLVCOIFF-UHFFFAOYSA-N 4-(3-chlorophenyl)piperidin-4-ol Chemical compound C=1C=CC(Cl)=CC=1C1(O)CCNCC1 PDJGUVHLVCOIFF-UHFFFAOYSA-N 0.000 description 1
- QNLXJYQUWCNYBH-UHFFFAOYSA-N 4-(4-bromophenyl)piperidin-4-ol Chemical compound C=1C=C(Br)C=CC=1C1(O)CCNCC1 QNLXJYQUWCNYBH-UHFFFAOYSA-N 0.000 description 1
- GZJUXUFLUYLFEM-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-[3-(2-nitro-6h-benzo[c][1]benzoxepin-11-ylidene)propyl]piperidin-4-ol Chemical compound C1CN(CCC=C2C3=CC(=CC=C3OCC3=CC=CC=C32)[N+]([O-])=O)CCC1(O)C1=CC=C(Cl)C=C1 GZJUXUFLUYLFEM-UHFFFAOYSA-N 0.000 description 1
- INPMKRGBXOGSQE-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-[3-(5,6-dihydrodibenzo[1,2-a:1',2'-e][7]annulen-11-ylidene)propyl]piperidin-4-ol Chemical compound C1CN(CCC=C2C3=CC=CC=C3CCC3=CC=CC=C32)CCC1(O)C1=CC=C(Cl)C=C1 INPMKRGBXOGSQE-UHFFFAOYSA-N 0.000 description 1
- NOMDYCWXWHSGHV-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-[3-(7-cyclopentyloxy-6h-[1]benzoxepino[2,3-b]pyridin-5-ylidene)propyl]piperidin-4-ol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCC=C(C1=CC=CN=C1OC1=CC=C2)CC1=C2OC1CCCC1 NOMDYCWXWHSGHV-UHFFFAOYSA-N 0.000 description 1
- GCZJIFDZKRQAMP-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-[3-(dibenzo[1,2-a:1',2'-e][7]annulen-11-ylidene)propyl]piperidin-4-ol Chemical compound C1CN(CCC=C2C3=CC=CC=C3C=CC3=CC=CC=C32)CCC1(O)C1=CC=C(Cl)C=C1 GCZJIFDZKRQAMP-UHFFFAOYSA-N 0.000 description 1
- QUGSLMDKNKCDMJ-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-[3-[7-(2-hydroxy-2-methylpropoxy)-6h-[1]benzoxepino[2,3-b]pyridin-5-ylidene]propyl]piperidin-4-ol Chemical compound C1C=2C(OCC(C)(O)C)=CC=CC=2OC2=NC=CC=C2C1=CCCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 QUGSLMDKNKCDMJ-UHFFFAOYSA-N 0.000 description 1
- HGMSNMHQOHEEBI-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-[3-[7-(2-hydroxyethoxy)-6h-[1]benzoxepino[2,3-b]pyridin-5-ylidene]propyl]piperidin-4-ol Chemical compound C1C=2C(OCCO)=CC=CC=2OC2=NC=CC=C2C1=CCCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 HGMSNMHQOHEEBI-UHFFFAOYSA-N 0.000 description 1
- IOJQKXCYEMVZIL-UHFFFAOYSA-N 4-(4-chlorophenyl)-1-[4-(7-methoxy-6h-[1]benzoxepino[2,3-b]pyridin-5-ylidene)but-1-en-2-yl]piperidin-4-ol Chemical compound C1C=2C(OC)=CC=CC=2OC2=NC=CC=C2C1=CCC(=C)N(CC1)CCC1(O)C1=CC=C(Cl)C=C1 IOJQKXCYEMVZIL-UHFFFAOYSA-N 0.000 description 1
- MNUZBWLIPUZYOV-UHFFFAOYSA-N 4-(4-fluoro-3-methylphenyl)piperidin-4-ol Chemical compound C1=C(F)C(C)=CC(C2(O)CCNCC2)=C1 MNUZBWLIPUZYOV-UHFFFAOYSA-N 0.000 description 1
- QXWRXWPNHLIZBV-UHFFFAOYSA-N 4-(4-fluorophenyl)piperidin-4-ol Chemical compound C=1C=C(F)C=CC=1C1(O)CCNCC1 QXWRXWPNHLIZBV-UHFFFAOYSA-N 0.000 description 1
- ZIYRFSOIBBGGDC-UHFFFAOYSA-N 4-(4-hydroxyphenyl)piperidin-4-ol Chemical compound C1=CC(O)=CC=C1C1(O)CCNCC1 ZIYRFSOIBBGGDC-UHFFFAOYSA-N 0.000 description 1
- WKBHGQDRVYFORB-UHFFFAOYSA-N 4-(4-hydroxypiperidin-4-yl)benzonitrile Chemical compound C=1C=C(C#N)C=CC=1C1(O)CCNCC1 WKBHGQDRVYFORB-UHFFFAOYSA-N 0.000 description 1
- RGFHJSYBDBNFMX-UHFFFAOYSA-N 4-(4-methoxyphenyl)piperidin-4-ol Chemical compound C1=CC(OC)=CC=C1C1(O)CCNCC1 RGFHJSYBDBNFMX-UHFFFAOYSA-N 0.000 description 1
- MEFDFYOJQUOHCR-UHFFFAOYSA-N 4-(4-methylphenyl)piperidin-4-ol Chemical compound C1=CC(C)=CC=C1C1(O)CCNCC1 MEFDFYOJQUOHCR-UHFFFAOYSA-N 0.000 description 1
- VELLXNGRWGRZRH-UHFFFAOYSA-N 4-(5-chloropyridin-2-yl)piperidin-4-ol Chemical compound C=1C=C(Cl)C=NC=1C1(O)CCNCC1 VELLXNGRWGRZRH-UHFFFAOYSA-N 0.000 description 1
- KZZLCYKEVNALMG-UHFFFAOYSA-N 4-[4-(trifluoromethyl)phenyl]piperidin-4-ol Chemical compound C=1C=C(C(F)(F)F)C=CC=1C1(O)CCNCC1 KZZLCYKEVNALMG-UHFFFAOYSA-N 0.000 description 1
- RALRVIPTUXSBPO-UHFFFAOYSA-N 4-[4-chloro-3-(trifluoromethyl)phenyl]piperidin-4-ol Chemical group C=1C=C(Cl)C(C(F)(F)F)=CC=1C1(O)CCNCC1 RALRVIPTUXSBPO-UHFFFAOYSA-N 0.000 description 1
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 1
- WAIIZELGDHTPRX-UHFFFAOYSA-N 4-anilinopiperidine-4-carboxamide Chemical compound C=1C=CC=CC=1NC1(C(=O)N)CCNCC1 WAIIZELGDHTPRX-UHFFFAOYSA-N 0.000 description 1
- WREJQDFONWGRGI-UHFFFAOYSA-N 4-azido-4-(4-chlorophenyl)piperidine Chemical compound C1=CC(Cl)=CC=C1C1(N=[N+]=[N-])CCNCC1 WREJQDFONWGRGI-UHFFFAOYSA-N 0.000 description 1
- KJZBZOFESQSBCV-UHFFFAOYSA-N 4-benzylpiperidin-4-ol Chemical compound C=1C=CC=CC=1CC1(O)CCNCC1 KJZBZOFESQSBCV-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- KQKFQBTWXOGINC-UHFFFAOYSA-N 4-phenylpiperidin-4-ol Chemical compound C=1C=CC=CC=1C1(O)CCNCC1 KQKFQBTWXOGINC-UHFFFAOYSA-N 0.000 description 1
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical compound C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 description 1
- DMCVVFIWYIKAEJ-UHFFFAOYSA-N 4-phenylpiperidine-4-carbonitrile Chemical compound C=1C=CC=CC=1C1(C#N)CCNCC1 DMCVVFIWYIKAEJ-UHFFFAOYSA-N 0.000 description 1
- ZDEWVCFSCQUKTE-UHFFFAOYSA-N 4-piperidin-4-ylphenol Chemical compound C1=CC(O)=CC=C1C1CCNCC1 ZDEWVCFSCQUKTE-UHFFFAOYSA-N 0.000 description 1
- BUJRWALNQXWLLK-UHFFFAOYSA-N 4-pyridin-2-ylpiperidin-4-ol Chemical compound C=1C=CC=NC=1C1(O)CCNCC1 BUJRWALNQXWLLK-UHFFFAOYSA-N 0.000 description 1
- VVJAZRLYMFLGML-UHFFFAOYSA-N 4-pyridin-3-ylpiperidin-4-ol Chemical compound C=1C=CN=CC=1C1(O)CCNCC1 VVJAZRLYMFLGML-UHFFFAOYSA-N 0.000 description 1
- BMUVABKFVGHPFS-UHFFFAOYSA-N 4-pyridin-4-ylpiperidin-4-ol Chemical compound C=1C=NC=CC=1C1(O)CCNCC1 BMUVABKFVGHPFS-UHFFFAOYSA-N 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- UEQDSBHSVBVOJC-UHFFFAOYSA-N 4h-thieno[3,2-c][1]benzoxepin-10-one Chemical compound C1OC2=CC=CC=C2C(=O)C2=C1C=CS2 UEQDSBHSVBVOJC-UHFFFAOYSA-N 0.000 description 1
- IJOLHEQJZYRTLM-UHFFFAOYSA-N 5-(3-bromopropylidene)-6h-[1]benzoxepino[2,3-b]pyridin-7-ol Chemical compound O1C2=NC=CC=C2C(=CCCBr)CC2=C1C=CC=C2O IJOLHEQJZYRTLM-UHFFFAOYSA-N 0.000 description 1
- CDERLSJBZYXNHW-UHFFFAOYSA-N 5-(3-bromopropylidene)-6h-[1]benzoxepino[2,3-b]pyridine Chemical compound BrCCC=C1CC2=CC=CC=C2OC2=NC=CC=C12 CDERLSJBZYXNHW-UHFFFAOYSA-N 0.000 description 1
- CYAYCOCJAVHQSD-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid Chemical compound CC=1C(C(O)=O)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 CYAYCOCJAVHQSD-UHFFFAOYSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- CQOAMXQYKCRSFJ-UHFFFAOYSA-N 5-(chloromethyl)-2-trityltetrazole Chemical compound N1=C(CCl)N=NN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 CQOAMXQYKCRSFJ-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- PZKPGYRLIYGSLR-UHFFFAOYSA-N 5-[3-[4-(3-chlorophenyl)sulfonylpiperazin-1-yl]propylidene]-7-methoxy-6h-[1]benzoxepino[2,3-b]pyridine Chemical compound C1C=2C(OC)=CC=CC=2OC2=NC=CC=C2C1=CCCN(CC1)CCN1S(=O)(=O)C1=CC=CC(Cl)=C1 PZKPGYRLIYGSLR-UHFFFAOYSA-N 0.000 description 1
- CQQNQEMYQJERCC-UHFFFAOYSA-N 5-[3-[4-(4-chlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]propylidene]-7-methoxy-6h-[1]benzoxepino[2,3-b]pyridine Chemical compound C1C=2C(OC)=CC=CC=2OC2=NC=CC=C2C1=CCCN(CC=1)CCC=1C1=CC=C(Cl)C=C1 CQQNQEMYQJERCC-UHFFFAOYSA-N 0.000 description 1
- LZSJERDOHSHLFX-UHFFFAOYSA-N 5-[3-[4-(4-chlorophenyl)piperidin-1-yl]propylidene]-6h-[1]benzoxepino[2,3-b]pyridin-7-ol Chemical compound C1C=2C(O)=CC=CC=2OC2=NC=CC=C2C1=CCCN(CC1)CCC1C1=CC=C(Cl)C=C1 LZSJERDOHSHLFX-UHFFFAOYSA-N 0.000 description 1
- FFIQSIZDVAOBPC-UHFFFAOYSA-N 5-[3-[4-(4-chlorophenyl)piperidin-1-yl]propylidene]-6h-[1]benzoxepino[2,3-b]pyridine-8-carboxylic acid Chemical compound C1C2=CC(C(=O)O)=CC=C2OC2=NC=CC=C2C1=CCCN(CC1)CCC1C1=CC=C(Cl)C=C1 FFIQSIZDVAOBPC-UHFFFAOYSA-N 0.000 description 1
- FWBKCXVMXGWGKH-UHFFFAOYSA-N 5-[3-[4-(4-chlorophenyl)piperidin-1-yl]propylidene]-7-ethoxy-6h-[1]benzoxepino[2,3-b]pyridine Chemical compound C1C=2C(OCC)=CC=CC=2OC2=NC=CC=C2C1=CCCN(CC1)CCC1C1=CC=C(Cl)C=C1 FWBKCXVMXGWGKH-UHFFFAOYSA-N 0.000 description 1
- OYAOTYKUDCIZLP-UHFFFAOYSA-N 5-[3-[4-(7-chloro-1h-indol-3-yl)piperidin-1-yl]propylidene]-7-methoxy-6h-[1]benzoxepino[2,3-b]pyridine Chemical compound C1C=2C(OC)=CC=CC=2OC2=NC=CC=C2C1=CCCN1CCC(C=2C3=CC=CC(Cl)=C3NC=2)CC1 OYAOTYKUDCIZLP-UHFFFAOYSA-N 0.000 description 1
- DOAYWDKFDPSTSV-UHFFFAOYSA-N 5-chloro-1,3-dihydro-1-(4-piperidinyl)-2h-benzimidazol-2-one Chemical compound O=C1NC2=CC(Cl)=CC=C2N1C1CCNCC1 DOAYWDKFDPSTSV-UHFFFAOYSA-N 0.000 description 1
- IBFOZXTZOYXRPP-UHFFFAOYSA-N 5-cyclopropyl-7-methoxy-6h-[1]benzoxepino[2,3-b]pyridin-5-ol Chemical compound C1C=2C(OC)=CC=CC=2OC2=NC=CC=C2C1(O)C1CC1 IBFOZXTZOYXRPP-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- FQYQTPXZOPAYOY-UHFFFAOYSA-N 5h-pyrido[2,3-c][2]benzazepine-6,11-dione Chemical group O=C1NC2=NC=CC=C2C(=O)C2=CC=CC=C12 FQYQTPXZOPAYOY-UHFFFAOYSA-N 0.000 description 1
- BKGPHKFLFHYDAV-UHFFFAOYSA-N 6-methylspiro[1h-3,1-benzoxazine-4,4'-piperidine]-2-one Chemical group C12=CC(C)=CC=C2NC(=O)OC21CCNCC2 BKGPHKFLFHYDAV-UHFFFAOYSA-N 0.000 description 1
- NZXADLPZIPVRPK-UHFFFAOYSA-N 6h-[1]benzothiepino[2,3-b]pyridin-5-one Chemical compound O=C1CC2=CC=CC=C2SC2=NC=CC=C12 NZXADLPZIPVRPK-UHFFFAOYSA-N 0.000 description 1
- XNJRBVRTKXCVMU-UHFFFAOYSA-N 6h-[1]benzoxepino[2,3-b]pyridin-5-one Chemical compound O=C1CC2=CC=CC=C2OC2=NC=CC=C12 XNJRBVRTKXCVMU-UHFFFAOYSA-N 0.000 description 1
- WIQCMQLBKMEVQS-UHFFFAOYSA-N 7-chloro-3-(1,2,3,6-tetrahydropyridin-4-yl)-1h-indole Chemical compound C=1NC=2C(Cl)=CC=CC=2C=1C1=CCNCC1 WIQCMQLBKMEVQS-UHFFFAOYSA-N 0.000 description 1
- KPBSLAAIZYQWOJ-UHFFFAOYSA-N 7-chloro-3-piperidin-4-yl-1,2-benzoxazole Chemical compound N=1OC=2C(Cl)=CC=CC=2C=1C1CCNCC1 KPBSLAAIZYQWOJ-UHFFFAOYSA-N 0.000 description 1
- CYQAPXIAEFXKPZ-UHFFFAOYSA-N 7-chloro-3-piperidin-4-yl-1h-indole Chemical compound C=1NC=2C(Cl)=CC=CC=2C=1C1CCNCC1 CYQAPXIAEFXKPZ-UHFFFAOYSA-N 0.000 description 1
- QAQWITVIYIELNQ-UHFFFAOYSA-N 7-methoxy-5,6-dihydro-[1]benzoxepino[2,3-b]pyridine Chemical group COC1=CC=CC2=C1CCC=1C(=NC=CC=1)O2 QAQWITVIYIELNQ-UHFFFAOYSA-N 0.000 description 1
- ONFADTQEEJPNIV-UHFFFAOYSA-N 7-methoxy-5-methylidene-6h-[1]benzoxepino[2,3-b]pyridine Chemical group O1C2=NC=CC=C2C(=C)CC2=C1C=CC=C2OC ONFADTQEEJPNIV-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- RVVFSQQXUOONDW-UHFFFAOYSA-N 8-bromo-10-(3-bromopropylidene)-4h-thieno[3,2-c][1]benzoxepine Chemical compound C1OC2=CC=C(Br)C=C2C(=CCCBr)C2=C1C=CS2 RVVFSQQXUOONDW-UHFFFAOYSA-N 0.000 description 1
- JPYSSLLFEBEVHG-UHFFFAOYSA-N 8-bromo-5-(3-bromopropylidene)-6h-[1]benzoxepino[2,3-b]pyridine Chemical compound BrCCC=C1CC2=CC(Br)=CC=C2OC2=NC=CC=C12 JPYSSLLFEBEVHG-UHFFFAOYSA-N 0.000 description 1
- JVKLJRIVVFWFME-UHFFFAOYSA-N 8-bromo-6h-[1]benzoxepino[2,3-b]pyridin-5-one Chemical compound O=C1CC2=CC(Br)=CC=C2OC2=NC=CC=C21 JVKLJRIVVFWFME-UHFFFAOYSA-N 0.000 description 1
- KPUOBVGSQUURIN-UHFFFAOYSA-N 9-methoxy-11-methylidene-5h-[1]benzoxepino[3,4-b]pyridine Chemical compound O1CC2=NC=CC=C2C(=C)C2=CC(OC)=CC=C21 KPUOBVGSQUURIN-UHFFFAOYSA-N 0.000 description 1
- GCADCMKFQZVUHX-UHFFFAOYSA-N 9-methoxy-5h-[1]benzoxepino[3,4-b]pyridin-11-one Chemical compound O1CC2=NC=CC=C2C(=O)C2=CC(OC)=CC=C21 GCADCMKFQZVUHX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- IMKDRTUMXIIHHK-UHFFFAOYSA-N C1C=CC(CN1CCC=C2CC3=C(C=CC=C3OC4=C2C=CC=N4)O)C5=CC=C(C=C5)Cl Chemical compound C1C=CC(CN1CCC=C2CC3=C(C=CC=C3OC4=C2C=CC=N4)O)C5=CC=C(C=C5)Cl IMKDRTUMXIIHHK-UHFFFAOYSA-N 0.000 description 1
- 102000018211 CC chemokine receptor 1 Human genes 0.000 description 1
- 108091008927 CC chemokine receptors Proteins 0.000 description 1
- DDVVSZIBQBCRMW-UHFFFAOYSA-N CC(C)(C(=O)N(C)C)OC1=CC=CC2=C1CC(=CCCN3CCC(CC3C4=CC=C(C=C4)Cl)O)C5=C(O2)N=CC=C5 Chemical compound CC(C)(C(=O)N(C)C)OC1=CC=CC2=C1CC(=CCCN3CCC(CC3C4=CC=C(C=C4)Cl)O)C5=C(O2)N=CC=C5 DDVVSZIBQBCRMW-UHFFFAOYSA-N 0.000 description 1
- 102000005674 CCR Receptors Human genes 0.000 description 1
- 108010017319 CCR1 Receptors Proteins 0.000 description 1
- OMUFNBAUAJORSF-UHFFFAOYSA-N COC1=CC=CC(OC2=NC=CC=C22)=C1CC2=CCCN1CC(C(C2=CC=C3)=CNC2=C3Cl)=CCC1 Chemical compound COC1=CC=CC(OC2=NC=CC=C22)=C1CC2=CCCN1CC(C(C2=CC=C3)=CNC2=C3Cl)=CCC1 OMUFNBAUAJORSF-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229940122444 Chemokine receptor antagonist Drugs 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
- 101100219997 Mus musculus Ccr1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 1
- UCBQSMFGCKUNIG-UHFFFAOYSA-N O1C2=NC=CC=C2C(=CCC=O)CC2=C1C=CC=C2OC Chemical compound O1C2=NC=CC=C2C(=CCC=O)CC2=C1C=CC=C2OC UCBQSMFGCKUNIG-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 206010037876 Rash papular Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- PBEGUZILPWUYGX-UHFFFAOYSA-N [1]benzoxepino[2,3-b]pyridine Chemical compound C1=CC2=CC=CN=C2OC2=CC=CC=C21 PBEGUZILPWUYGX-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 150000005130 benzoxazines Chemical class 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Substances OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229940006460 bromide ion Drugs 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- KMGBZBJJOKUPIA-UHFFFAOYSA-N butyl iodide Chemical compound CCCCI KMGBZBJJOKUPIA-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002559 chemokine receptor antagonist Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical group C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Chemical group 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000007646 directional migration Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- YRVLPWRWYCGESH-UHFFFAOYSA-N ethyl 2-[[5-[3-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]propylidene]-6h-[1]benzoxepino[2,3-b]pyridin-7-yl]oxy]propanoate Chemical compound C1C=2C(OC(C)C(=O)OCC)=CC=CC=2OC2=NC=CC=C2C1=CCCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 YRVLPWRWYCGESH-UHFFFAOYSA-N 0.000 description 1
- WJVHZFCVVZKIQE-UHFFFAOYSA-N ethyl 2-[[5-[3-[4-(4-chlorophenyl)piperidin-1-yl]propylidene]-6h-[1]benzoxepino[2,3-b]pyridin-7-yl]oxy]acetate Chemical compound C1C=2C(OCC(=O)OCC)=CC=CC=2OC2=NC=CC=C2C1=CCCN(CC1)CCC1C1=CC=C(Cl)C=C1 WJVHZFCVVZKIQE-UHFFFAOYSA-N 0.000 description 1
- IOLQWGVDEFWYNP-UHFFFAOYSA-N ethyl 2-bromo-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)Br IOLQWGVDEFWYNP-UHFFFAOYSA-N 0.000 description 1
- NVYFOAIDPCMXGS-UHFFFAOYSA-N ethyl 2-bromocyclobutane-1-carboxylate Chemical compound CCOC(=O)C1CCC1Br NVYFOAIDPCMXGS-UHFFFAOYSA-N 0.000 description 1
- ARFLASKVLJTEJD-UHFFFAOYSA-N ethyl 2-bromopropanoate Chemical compound CCOC(=O)C(C)Br ARFLASKVLJTEJD-UHFFFAOYSA-N 0.000 description 1
- XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical compound CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- SADPINFEWFPMEA-UHFFFAOYSA-N furan-2-yl(piperazin-1-yl)methanone Chemical compound C=1C=COC=1C(=O)N1CCNCC1 SADPINFEWFPMEA-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000011268 leukocyte chemotaxis Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 108010017286 macrophage inflammatory protein 1alpha receptor Proteins 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- NGZLMMNFHIJKRL-UHFFFAOYSA-N methyl 11-[3-[2-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]propylidene]-6h-benzo[c][1]benzoxepine-1-carboxylate Chemical compound C1=2C(C(=O)OC)=CC=CC=2OCC2=CC=CC=C2C1=CCCN1CCC(O)CC1C1=CC=C(Cl)C=C1 NGZLMMNFHIJKRL-UHFFFAOYSA-N 0.000 description 1
- LILBFDRUWNORGR-UHFFFAOYSA-N methyl 11-[3-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]propylidene]-6h-benzo[c][1]benzoxepine-2-carboxylate Chemical compound C12=CC(C(=O)OC)=CC=C2OCC2=CC=CC=C2C1=CCCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 LILBFDRUWNORGR-UHFFFAOYSA-N 0.000 description 1
- KUISDPUHRPZRFF-UHFFFAOYSA-N methyl 4-phenylpiperidine-4-carboxylate Chemical compound C=1C=CC=CC=1C1(C(=O)OC)CCNCC1 KUISDPUHRPZRFF-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- KCOHNRMFXQLTCW-UHFFFAOYSA-N n-(4-chlorophenyl)piperidin-4-amine Chemical compound C1=CC(Cl)=CC=C1NC1CCNCC1 KCOHNRMFXQLTCW-UHFFFAOYSA-N 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- ZDXPLBKUXYRHHM-UHFFFAOYSA-N oxolan-2-yl(diphenyl)phosphane Chemical compound C1COC(C1)P(c1ccccc1)c1ccccc1 ZDXPLBKUXYRHHM-UHFFFAOYSA-N 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 208000012963 papular rash Diseases 0.000 description 1
- UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Chemical compound [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- LJZPPWWHKPGCHS-UHFFFAOYSA-N propargyl chloride Chemical compound ClCC#C LJZPPWWHKPGCHS-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- YLGRTLMDMVAFNI-UHFFFAOYSA-N tributyl(prop-2-enyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)CC=C YLGRTLMDMVAFNI-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1032098A | 1998-01-21 | 1998-01-21 | |
| US09/010,320 | 1998-01-21 | ||
| US09/148,823 | 1998-09-04 | ||
| US09/148,823 US6613905B1 (en) | 1998-01-21 | 1998-09-04 | Chemokine receptor antagonists and methods of use therefor |
| PCT/US1999/001266 WO1999037651A1 (en) | 1998-01-21 | 1999-01-21 | Chemokine receptor antagonists and methods of use therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002501072A JP2002501072A (ja) | 2002-01-15 |
| JP2002501072A5 true JP2002501072A5 (https=) | 2006-03-16 |
| JP4853934B2 JP4853934B2 (ja) | 2012-01-11 |
Family
ID=27765167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000528572A Expired - Fee Related JP4853934B2 (ja) | 1998-01-21 | 1999-01-21 | ケモカイン受容体アンタゴニストおよびその使用方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US6613905B1 (https=) |
| JP (1) | JP4853934B2 (https=) |
| KR (1) | KR20010034291A (https=) |
| EA (1) | EA200000693A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6509346B2 (en) * | 1998-01-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| US7271176B2 (en) * | 1998-09-04 | 2007-09-18 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use thereof |
| US6518286B1 (en) * | 1999-03-26 | 2003-02-11 | Astrazeneca Ab | Compounds |
| US7541365B2 (en) * | 2001-11-21 | 2009-06-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| TWI291467B (en) * | 2002-11-13 | 2007-12-21 | Millennium Pharm Inc | CCR1 antagonists and methods of use therefor |
| US7214703B2 (en) * | 2003-02-12 | 2007-05-08 | Boehringer Ingelheim International Gmbh | Pyrrolidinohydrochinazolines |
| US20070066570A1 (en) * | 2003-06-16 | 2007-03-22 | Michael Solomon | Methods for treating sleep disorders |
| ATE553761T1 (de) | 2004-12-17 | 2012-05-15 | Millennium Pharm Inc | Solide formen eines chemokin-rezeptorantagonisten und anwendungsverfahren dafür |
| EP1866298A2 (en) * | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| US20090286823A1 (en) * | 2007-12-17 | 2009-11-19 | Millennium Pharmaceuticals Inc. | CCR1 Inhibitors useful for the treatment of multiple myeloma and other disorders |
| JP5379139B2 (ja) * | 2008-08-01 | 2013-12-25 | 日本臓器製薬株式会社 | アミノプロピリデン誘導体 |
| WO2012163848A1 (en) * | 2011-05-27 | 2012-12-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of crohn's disease |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE80449C (https=) | ||||
| GB1003292A (en) | 1960-12-08 | 1965-09-02 | Sandoz Ag | Improvements in or relating to 4-azathiaxanthene derivatives |
| BE664609A (https=) | 1964-06-01 | |||
| CH421138A (de) | 1965-11-04 | 1966-09-30 | Wander Ag Dr A | Verfahren zur Herstellung von Thioxanthenderivaten |
| US3409621A (en) | 1966-04-01 | 1968-11-05 | Schering Corp | Piperazino-aza-dibenzo-[a, d]-cycloheptenes |
| US3625974A (en) | 1967-04-28 | 1971-12-07 | Fujisawa Pharmaceutical Co | Dibenzothiazepine derivatives |
| NL6905642A (https=) | 1968-04-12 | 1969-10-14 | ||
| JPS4830064B1 (https=) * | 1968-12-23 | 1973-09-17 | ||
| US3770729A (en) | 1970-12-22 | 1973-11-06 | Yoshitomi Pharmaceutical | N substituted piperidine compounds |
| GB1330966A (en) | 1970-12-22 | 1973-09-19 | Yoshitomi Pharmaceutical | N-substituted piperidine compounds methods for their production and pharmaceutical compositions containing them |
| JPS4921150B1 (https=) * | 1970-12-28 | 1974-05-30 | ||
| JPS4921151B1 (https=) * | 1970-12-25 | 1974-05-30 | ||
| JPS4920790B1 (https=) * | 1970-12-22 | 1974-05-27 | ||
| CA1010870A (en) * | 1972-12-08 | 1977-05-24 | Niels Lassen | Thiaxanthene derivative and method |
| US4250176A (en) | 1976-12-21 | 1981-02-10 | Janssen Pharmaceutica N.V. | Piperazine derivatives |
| US4335122A (en) | 1981-03-18 | 1982-06-15 | Hoechst-Roussel Pharmaceuticals Inc. | Dihydro-dibenzoxepines-thiepines and -morphanthridones, compositions and use |
| DE3326641A1 (de) | 1982-07-27 | 1984-02-02 | Basf Ag, 6700 Ludwigshafen | 5,6-dihydro-11-h-morphantridin-6-one, ihre herstellung und diese enthaltende arzneimittel |
| CA1237428A (en) | 1983-06-24 | 1988-05-31 | Hiroshi Tanaka | ¬1| benzepino¬3,4-b|pyridine derivative |
| ES8502099A1 (es) * | 1983-08-02 | 1984-12-16 | Espanola Farma Therapeut | Procedimiento de obtencion de nuevos compuestos derivados de la difenil-metilen-etilamina. |
| DE3402060A1 (de) | 1984-01-21 | 1985-08-01 | Dr. Karl Thomae Gmbh, 7950 Biberach | Substituierte 5,11-dihydro-6h-dibenz(b,e)azepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| JPH0665664B2 (ja) | 1985-01-18 | 1994-08-24 | 大塚製薬株式会社 | モルフアントリジン誘導体 |
| SE8500273D0 (sv) | 1985-01-22 | 1985-01-22 | Leo Ab | Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder |
| JPS6310784A (ja) * | 1986-03-03 | 1988-01-18 | Kyowa Hakko Kogyo Co Ltd | 抗アレルギー剤 |
| US5089496A (en) | 1986-10-31 | 1992-02-18 | Schering Corporation | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies |
| IT8721978A0 (it) | 1987-09-21 | 1987-09-21 | Angeli Inst Spa | Nuovi derivati ammidinici triciclici. |
| US4882351A (en) | 1987-10-14 | 1989-11-21 | Roussel Uclaf | Tricyclic compounds |
| AU612437B2 (en) | 1987-12-14 | 1991-07-11 | Kyowa Hakko Kogyo Co. Ltd. | Tricyclic compounds |
| EP0411048A1 (en) | 1988-04-28 | 1991-02-06 | Schering Corporation | Novel benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use |
| US5242931A (en) | 1988-06-09 | 1993-09-07 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds as TXA2 antagonists |
| CA1338625C (en) | 1988-06-09 | 1996-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| DE3838912A1 (de) | 1988-11-17 | 1990-05-23 | Thomae Gmbh Dr K | Mittel zur behandlung von akuten und chronischen obstruktiven atemwegserkrankungen |
| JPH0694464B2 (ja) | 1991-01-23 | 1994-11-24 | 協和醗酵工業株式会社 | 三環式化合物およびその中間体 |
| EP0511477B1 (en) | 1991-03-11 | 1996-07-10 | Kyowa Hakko Kogyo Co., Ltd. | Indole derivatives |
| WO1992016226A1 (en) | 1991-03-19 | 1992-10-01 | Smithkline Beecham Corporation | Il-1 inhibitors |
| WO1992020681A1 (en) | 1991-05-23 | 1992-11-26 | Schering Corporation | Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use |
| WO1993002081A1 (en) | 1991-07-23 | 1993-02-04 | Schering Corporation | Novel benzopyrido piperylidene compounds, compositions, methods of manufacture and methods of use |
| US5378701A (en) | 1991-12-27 | 1995-01-03 | Kyowa Hakko Kogyo | Tricyclic compounds |
| US5679703A (en) | 1992-09-16 | 1997-10-21 | Kyowa Hakko Kogyo, Co., Ltd. | Tricyclic compounds having ACAT inhibiting activity |
| US5538986A (en) | 1993-12-06 | 1996-07-23 | Schering Corporation | Tricyclic derivatives, compositions and methods of use |
| MY113463A (en) | 1994-01-04 | 2002-03-30 | Novo Nordisk As | Novel heterocyclic compounds |
| AU5270796A (en) | 1995-04-07 | 1996-10-23 | Novo Nordisk A/S | N-substituted azaheterocyclic carboxylic acids and esters th ereof |
| US5712280A (en) | 1995-04-07 | 1998-01-27 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| UA54385C2 (uk) | 1995-04-07 | 2003-03-17 | Ново Нордіск А/С | N-заміщені азагетероциклічні карбонові кислоти та їх ефіри, спосіб їх одержання, фармацевтична композиція та спосіб лікування |
| US5801175A (en) | 1995-04-07 | 1998-09-01 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| WO1996031470A1 (en) | 1995-04-07 | 1996-10-10 | Novo Nordisk A/S | Novel heterocyclic compounds |
| JPH0940662A (ja) | 1995-05-24 | 1997-02-10 | Kyowa Hakko Kogyo Co Ltd | 三環式化合物 |
| US6150355A (en) | 1995-09-13 | 2000-11-21 | Kyowa Hakko Kogyo Co., Ltd. | Phenylpiperidine derivative |
| AU1208397A (en) | 1995-12-28 | 1997-07-28 | Takeda Chemical Industries Ltd. | Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists |
| DE69709647T2 (de) | 1996-05-20 | 2002-11-07 | Dupont Pharmaceuticals Research Laboratories, Inc. | Cyclischer diarylalkyl diaminederivate als antogoniste von chemokinerezeptoren |
| US6323206B1 (en) | 1996-07-12 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| JP2000516210A (ja) | 1996-07-12 | 2000-12-05 | ロイコサイト,インコーポレーテッド | ケモカインレセプターアンタゴニストとその使用方法 |
| CA2261633A1 (en) | 1996-07-29 | 1998-02-05 | Banyu Pharmaceutical Co., Ltd. | Chemokine receptor antagonists |
| AU4801197A (en) | 1996-09-13 | 1998-04-02 | Schering Corporation | Tricyclic antitumor compounds being farnesyl protein transferase inhibit ors |
| NZ334437A (en) | 1996-09-13 | 2000-09-29 | Schering Corp | Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase |
| CZ84199A3 (cs) | 1996-09-13 | 1999-11-17 | Schering Corporation | Nové, tricyklické piperidinylové sloučeniny použitelné jako inhibitory farnesylprotein transferasy |
| CA2264666A1 (en) | 1996-09-13 | 1998-03-19 | Schering Corporation | Substituted benzocycloheptapyridine useful as inhibitors of farnesyl-protein transferase |
| IL128949A0 (en) | 1996-09-13 | 2000-02-17 | Schering Corp | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| CN1104427C (zh) | 1996-09-13 | 2003-04-02 | 先灵公司 | 法呢基蛋白转移酶的三环抑制剂 |
| CN1237176A (zh) | 1996-09-13 | 1999-12-01 | 先灵公司 | 用作fpt抑制剂的三环化合物 |
| WO1998015548A1 (en) * | 1996-10-04 | 1998-04-16 | Novo Nordisk A/S | 1,4-disubstituted piperazines |
| CA2267500A1 (en) | 1996-10-04 | 1998-04-16 | Novo Nordisk A/S | N-substituted azaheterocyclic compounds |
| ZA978792B (en) * | 1996-10-04 | 1998-04-06 | Novo Nordisk As | N-substituted azaheterocyclic compounds. |
| AU5522498A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| AU5604998A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
| WO1998025605A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
| AU5812498A (en) | 1996-12-20 | 1998-07-17 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
| US5919776A (en) * | 1996-12-20 | 1999-07-06 | Merck & Co., Inc. | Substituted aminoquinolines as modulators of chemokine receptor activity |
| AU6517398A (en) | 1997-03-27 | 1998-10-22 | Kyowa Hakko Kogyo Co. Ltd. | Therapeutic agent for autoimmune diseases |
| ES2273413T3 (es) | 1997-04-15 | 2007-05-01 | Kyowa Hakko Kogyo Co., Ltd. | Compuestos triciclicos. |
| US5877177A (en) | 1997-06-17 | 1999-03-02 | Schering Corporation | Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| JP2002515914A (ja) * | 1997-06-25 | 2002-05-28 | ノボ ノルディスク アクティーゼルスカブ | 新規へテロ環式化合物 |
| US6040318A (en) | 1997-06-25 | 2000-03-21 | Novo Nordisk A/S | Tricycle substituted with azaheterocyclic carboxylic acids |
| US6048856A (en) | 1997-12-17 | 2000-04-11 | Novo Nordisk A/S | Heterocyclic compounds |
| BR9910144A (pt) | 1998-01-21 | 2002-04-02 | Millennium Pharm Inc | Antagonistas de receptores de quimiocinas e seu uso |
| US6433165B1 (en) | 1998-01-21 | 2002-08-13 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| CA2343536A1 (en) | 1998-09-04 | 2000-03-16 | Yoshisuke Nakasato | Chemokine receptor antagonists and methods of use therefor |
-
1998
- 1998-09-04 US US09/148,823 patent/US6613905B1/en not_active Expired - Fee Related
-
1999
- 1999-01-21 KR KR1020007008006A patent/KR20010034291A/ko not_active Withdrawn
- 1999-01-21 JP JP2000528572A patent/JP4853934B2/ja not_active Expired - Fee Related
- 1999-01-21 EA EA200000693A patent/EA200000693A1/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4903333B2 (ja) | ケモカイン受容体アンタゴニストおよびその使用方法 | |
| US6329385B1 (en) | Chemokine receptor antagonists and methods of use therefor | |
| JP5936669B2 (ja) | ケモカイン受容体アンタゴニストおよびその使用方法 | |
| JP4853934B2 (ja) | ケモカイン受容体アンタゴニストおよびその使用方法 | |
| JP2002501072A5 (https=) | ||
| US20020169155A1 (en) | Chemokine receptor anagonists and methods of use therefor | |
| US9663537B2 (en) | Chemokine receptor antagonists and methods of use | |
| WO2003045942A2 (en) | Chemokine receptor antagonists and methods of use thereof | |
| US20050070549A1 (en) | Chemokine receptor antagonists and methods of use thereof | |
| MXPA00007140A (en) | Chemokine receptor antagonists and methods of use therefor |